well tolerated in the prevention
of CINV in patients with solid
tumours undergoing MEC or HEC.
The authors commented that
NEPA offers convenience and, as a
simple guideline-based regimen,
has the potential to improve
adherence to guidelines, improving
the CINV control for patients. 32–36
A significantly higher percentage
(76.9%) of patients treated with
NEPA plus a single dose of
dexamethasone achieved CR (no
emesis, no rescue medication)
than those treated with oral
palonosetron (69.5%; p=0.001) in
the delayed (25–120 hours) phase
following AC and in the acute
(0–24 hours) phase (88.4% versus
85%; p=0.047) as well as overall
(0–120 hours) (74.3% versus 66.6%;
p=0.001). 34
In a FLIE assessment performed
by Aapro et al in 2014, a greater
proportion of NEPA-treated
patients reported NIDL for the
nausea, vomiting and combined
domains compared with oral
palonosteron. 34
In a study by Hesketh et al in
694 chemotherapy-naïve patients
undergoing cisplatin-based
chemotherapy for solid tumours,
three different oral doses of NEPA
hospitalpharmacyeurope.com | 2019 | 39